< Key Hightlight >

MARKET OUTLOOK

Triton Market Research’s report suggests that the Asia-Pacific biosurgery market is probable to witness growth at a CAGR of 7.56% through the years 2021-2028. South Korea, Australia & New Zealand, India, ASEAN countries, Japan, China, and Rest of APAC form the market in this region.

In India, the rising burden of chronic diseases and the growing number of surgical procedures are key factors expected to augment the growth of the reviewed market during the estimated phase. For instance, in recent years, the number of patients suffering from cancer and cardiovascular diseases has increased. Moreover, as per estimates, the country is likely to witness an endemic of osteoarthritis in the next few years. This will ultimately enhance the demand for biosurgery products, in turn, offering new opportunities to the biosurgery market in India in the upcoming years. 

Furthermore, over the years, there has been substantial growth in knee replacement procedures for osteoarthritis within Australia. This increase is estimated to amplify the demand for biosurgery products. Additionally, several new products are launched in the country, which will further support the growth of the studied market. Besides, the rise in the geriatric population and the emergence of several lifestyle conditions have also enhanced the demand for biosurgery products. Hence, all these factors are responsible for positioning the Australian biosurgery market on a growth path. 

COMPETITIVE OUTLOOK

Some of the firms in the biosurgery market consist of Sanofi, Baxter International Inc, CSL Limited, Ethicon Inc (Johnson & Johnson), Integra Lifesciences Holdings Corporation, and Smith & Nephew Plc.